Genentech, Inc.

F. Hoffmann-la Roche Ag

Justin Scheer

Paul J Carter

Richard L Vandlen

Daniel G Yansura

Isidro Hotzel

Christoph Spiess

Wenjun Ouyang

Teemu T Junttila

Eric Gary Stefanich

Xiaoting Wang

Ji Li

Whitney Shatz

Diego Ellerman

Nicholas Van Bruggen

Ganesh A Kolumam

Danielle Dicara

Wyne Pun Lee

Glen Giese

Ambrose Williams

Domingos Ng

Jed Ross

J Michael Elliott

Philip E Haas

Amy Lim

Josefine Persson

Richard Vandlen

Wyne P Lee

The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.

Humanized and affinity matured antibodies to FcRH5 and methods of use

Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.

Production of heteromultimeric proteins using mammalian cells

Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.

Fc variants and methods for their production

Growing community of inventors

San Francisco, CA, United States of America

Justin Scheer